GeoVax Labs announced that the U.S. Patent and Trademark Office has issued Patent No. 11,857,611 to GeoVax, pursuant to the Company’s patent application No. 17/726,254 titled “Compositions and Methods for Generating an Immune Response to Treat or Prevent Malaria.” The claims granted by the patent generally cover compositions comprising GeoVax’s modified vaccinia Ankara vector expressing Plasmodium antigens and methods of inducing an immune response to malaria utilizing the compositions. The compositions and methods covered in the claims are useful both prophylactically and therapeutically and may be used to prevent and/or treat malaria.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GOVX:
- GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
- GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
- GeoVax Labs expands rights under NIH COVID-19 license to include Mpox, smallpox
- GeoVax to Participate in Upcoming December Investor Events
- GeoVax Labs announces COVID-19 vaccine data to be presented at WVC